US Take-Privates: Special Committees, Go-Shops and Closing

Introduction

A take-private is the one buyout in which the sponsor never negotiates with the people who own the company. When TowerBrook and Clayton, Dubilier & Rice (CD&R) agreed in 2024 to buy R1 RCM, a healthcare revenue-cycle company, for about $8.9 billion, the counterparty across the table was a special committee of two independent directors with two banks behind it, acting for public shareholders who never met the bidders. The committee's job was to secure a price and also to build a record that would survive a shareholder vote, Securities and Exchange Commission (SEC) review and, if challenged, a Delaware court.

That is the core difference from a private leveraged buyout (LBO). What a sponsor pays for a listed company is shaped by the target board's fiduciary duties, by which directors and shareholders are conflicted and must step aside, by the market check the board needs before it can recommend a cash sale, and by going-private disclosure that can put even the buyer's bankers' analysis on the public record. Those rules decide which seat each bank can take and what a sponsor must offer to win.

The sequence of a US take-private, from the first letter to delisting, is laid out in the take-private LBO process. From the sponsor seat, the useful view is how each part differs from buying a private company:

The second row comes from Delaware law, where many US targets are incorporated. Under the Revlon line of cases, once a board decides to sell control for cash, its duty is to seek the best value reasonably available to shareholders, and a cash sale to a sponsor is a sale of control. The board does not have to run an auction, but it needs a basis for believing no one would pay more. That basis is either a pre-signing market check, in which its bankers sound out likely buyers before a price is agreed, or a post-signing market check, in which the signed deal stays open to rivals through a go-shop or through deal protections modest enough that a higher bidder can still step in.

Sponsors that already hold stock face extra rules. A holder above 5% with intent to influence control reports on Schedule 13D and must amend it when its plans change, so a proposal from an existing shareholder tends to become public fast: New Mountain Capital's proposal for R1 appeared in its 13D amendment on the day it asked the board for permission to bid. Investor agreements often carry standstills that bar proposals without board consent, and Section 203 of the Delaware General Corporation Law (DGCL) blocks a business combination with a holder of 15% or more for three years unless the board approved it beforehand, which is why a shareholder that wants to team up with another large holder asks for a waiver first. "Walk me through a take-private" comes up often in interviews, and this is the distinction that organizes the answer: the board, not the owner, is the counterparty. Outside the US the same questions run through different machinery, described in UK take-privates and the Takeover Code.

A board can bargain for shareholders only if its members have nothing to gain on the other side. When a buyer is connected to the company, the conflicted directors step aside and a committee of independent directors takes over the negotiation, with its own lawyers and, usually, its own bankers.

Special Committee

A committee of independent, disinterested directors that a board empowers to evaluate, negotiate and, if it chooses, reject a transaction in which a controlling shareholder, management or other insiders have a conflicting interest. It typically hires its own legal and financial advisers, and its approval is the main evidence that the sale was negotiated at arm's length.

When a Take-Private Needs One

In sponsor take-privates, the usual triggers are:

The rollover and incentive terms that create the first conflict are examined in management buyouts and management rollover. Where no one on the board is conflicted, the full board negotiates, sometimes through a smaller transaction committee that handles the process day to day without curing any conflict; Everbridge's board, discussed below, used one.

Delaware's Controller Framework After SB 21

When the buyer is a controlling stockholder, Delaware courts have reviewed the deal for entire fairness, a demanding test of fair price and fair dealing. In Kahn v. M&F Worldwide (2014), the Delaware Supreme Court offered a way out: a controller buyout gets deferential business judgment review if it is conditioned from the outset on approval by an independent, empowered special committee and on an informed, uncoerced majority-of-the-minority vote.

Majority-of-the-Minority Condition

A term in a merger agreement making completion depend on approval by a majority of the shares held, or votes cast, by stockholders unaffiliated with the buyer, its affiliates and other interested holders. It gives the public holders a veto that the buyer's own votes cannot override.

Senate Bill 21 (SB 21), signed on March 25, 2025, wrote a version of that framework into Section 144 of the DGCL. The statute defines a controller as a holder of majority voting power, or of at least one-third of the vote combined with managerial authority. Other controller transactions can reach a safe harbor with either a committee approval or a vote of disinterested stockholders, but a going-private transaction needs both: approval or recommendation by a committee of at least two disinterested directors, and a majority of the votes cast by disinterested holders, with the deal conditioned on that vote when it goes to stockholders rather than from the first negotiation. The amendments apply to earlier transactions except where litigation was pending by February 17, 2025, and the Delaware Supreme Court upheld them in February 2026 in Rutledge v. Clearway Energy Group.

For the sponsor, a minority vote is a real cost. It hands a veto to the public holders, including event-driven funds that may buy shares after announcement to press for a higher price, so the bid has to satisfy them as well as the committee.

Federal disclosure adds a second layer. SEC Rule 13e-3 applies when the company or an affiliate, meaning a person that controls, is controlled by or is under common control with it, engages in a transaction likely to delist or deregister its shares. A sponsor with a significant stake and board seats, a controller, or a management group joining the buyer can all make the deal a Rule 13e-3 transaction.

Rule 13e-3 Transaction

A going-private transaction by a public company or one of its affiliates that is reasonably likely to cause a class of equity to be delisted or deregistered. The company and the affiliated buyers file a Schedule 13E-3, state whether they believe the deal is fair to unaffiliated holders, and disseminate the disclosure at least 20 days before the vote or purchase.

Two features matter to bankers. Each filing person, the buyer included, must take a public position on fairness to the unaffiliated holders and explain it. And any report, opinion or appraisal from an outside party that is materially related to the deal must be summarized, with the adviser's selection, relationships and compensation, so the bankers' board presentations are filed as exhibits. R1's Schedule 13E-3 listed discussion materials including sets from Barclays dated March 3, 2024, from Qatalyst Partners and Barclays dated April 17, July 1, July 5 and July 31, and presentations Centerview Partners made to TA, the TowerBrook vehicle, on July 3 and July 20.

The fee disclosure follows the same logic. In most sponsor acquisitions the buyer's advisory costs stay private, the gap described in buy-side advisory for sponsors; at R1 the buyer's adviser fee was printed in the proxy. On the target side, the structure of the opinion fee is read as a test of independence: both committee banks at R1 earned $7.5 million on delivering their opinions whatever the conclusion, with the rest of their pay tied to closing. What an opinion covers, and what it does not, is set out in how bankers deliver a fairness opinion.

The R1 RCM merger proxy shows a special committee managing the hardest version of the problem: two insider bidders, each with board designees and a large stake, competing for the company they partly owned.

Two Large Holders, Two Bids

New Mountain Capital had received about 30% of R1 when it merged its Cloudmed business into the company in 2022, and held about 32% by January 2024. TA, a vehicle owned by TowerBrook and Ascension, R1's largest customer, held about 36% including convertible securities. Both were bound by standstills. On January 26, 2024, New Mountain asked for a waiver to propose $13.75 a share; the board urged it to talk to TA instead, judging a joint bid more actionable. On March 7 the board formed a committee of two independent directors, who hired Qatalyst Partners and Barclays, after reviewing Barclays's past fees from the investor parties and judging them immaterial, plus Skadden as counsel.

The market check found little outside interest. After the committee was announced, nine sponsors, CD&R among them, called Barclays about co-investing alongside the two holders; none offered to bid alone. The reason was in the holders' own letters: TA told the board that a deal without both of them would be difficult, if not impossible, to execute, and neither said it would sell its stake to anyone else, so an outside sponsor would have had to buy a company whose two largest owners were not sellers. Five strategic buyers contacted in April declined by the end of May. The joint approach between the two holders collapsed on July 1 over post-closing governance, and New Mountain bid $13.25 alone. The committee countered at $15.00, New Mountain moved to $13.80, the committee countered at $14.40, and New Mountain reached $14.05 on July 6.

Sealed Final Bids on Finished Documents

TA then brought in CD&R as a partner, and the committee granted both the Section 203 waivers they needed. When TA and CD&R said they could not bid by the July 25 deadline, the committee extended it once, to July 31, but required both bidders to finalize every document except the price by July 24: the merger agreement, disclosure schedules and financing commitment letters. The bids could then differ only on price. On July 31 New Mountain offered $14.05 and TA and CD&R $14.30, each with executed commitments; both banks delivered fairness opinions and the agreement was signed that day. The premium, about 29%, was measured against the close on February 23, the last trading day before New Mountain's 13D amendment disclosed its proposal, because the later share price already carried the bid. Choosing that unaffected date is one of the first judgments in any take-private that leaks or starts with a public letter, since it decides how generous the headline premium looks. The finished-documents rule mattered as much as the price: insiders usually know the business better than outside bidders, and forcing both into identical paperwork and one deadline left the committee comparing two numbers rather than two bundles of conditions.

The signed terms show how much of the work a significant holder's stake had already done. Under a voting agreement, TA committed its 29.44% in favor, and the merger needed only a majority of all outstanding shares, with no separate minority condition, so TA's commitment covered more than half the votes required. The buyers carried a reverse termination fee of $550 million and no financing condition, with Centerview as lead adviser alongside Deutsche Bank and RBC, and debt from a group of banks and private credit lenders. The deal closed on November 19, 2024, and Joe Flanagan, a former chief executive who had helped the bidders' diligence and disclosed those contacts to the committee in writing, returned as chief executive.

A go-shop lets the target solicit rivals for a set window after signing, with a lower break fee if it accepts a superior offer from one of them; the clause itself is explained in what a go-shop period is. Sponsors usually concede one when the board has not run a broad auction before signing. The evidence on what they deliver is thin. In Go-Shops Revisited, Guhan Subramanian and Annie Zhao found that 7 of 114 go-shops in deals announced from 2010 to 2019 produced a higher bid, a jump rate of 6.1%, falling to 4.3% (2 of 46) in 2015 to 2019, against 12.5% in an earlier study of 2006 and 2007 deals. They pointed to match rights for the first bidder, shorter windows and executives' incentives to keep the price down.

Everbridge: A Go-Shop That Moved the Price

The Everbridge merger proxy shows the exception. In January 2024 Thoma Bravo, a frequent buyer in software take-privates, offered $27.00 a share for the critical event management software company, with a warning that the offer would not stay open long. A rival sponsor, identified only as Specified Party I, indicated $29.00 to $34.00, subject to debt financing it had not been allowed to seek. Thoma Bravo moved to $28.00, then $28.60 as its best and final price, and accepted a 25-day go-shop limited to parties that had been in discussions with the company in the previous six months, with a termination fee of 1.6% of equity value for a deal with one of them against 3.2% otherwise. The agreement was signed on February 4.

Signing removed Specified Party I's handicap, because a public announcement ended the leak risk of talking to lenders. It bid $31.00 that night and $32.00 on February 16, with $800 million of committed debt and executed documents held in escrow. Thoma Bravo matched at $32.00 with an equity commitment for the full purchase price and fewer foreign regulatory filings; Specified Party I went to $34.00; and on February 29 Thoma Bravo offered $35.00 at a board meeting, $6.40 above its signed price. The deal, valued at about $1.8 billion, closed on July 2, 2024, with Qatalyst Partners advising Everbridge and Raymond James advising Thoma Bravo.

Everbridge fits the evidence rather than contradicting it. The higher bidder was not found by the go-shop; it was a pre-signing bidder, deep in diligence, held back only by lender access, and the go-shop gave it a window and a lower fee to clear. Where no such party exists, a go-shop mostly adds a defensible step to the board's record, and the price is set before signing.

Signing a take-private opens months of execution risk that the sponsor carries through its financing, while each bank on the deal works for a different client with a different stake in the outcome.

Commitments Instead of a Financing Condition

Public targets will not accept a financing condition, so a sponsor signs with an equity commitment letter from its fund, debt commitment letters from its lenders, a limited guarantee and a reverse termination fee payable on specified failures to close: $550 million at R1, $124 million at Everbridge. Thoma Bravo's full equity commitment during the Everbridge contest went further, taking the debt markets out of the target's risk. How these documents divide closing risk is the subject of sponsor deal terms and certainty. The commitments also have to last. R1 signed on July 31 and closed on November 19, about 16 weeks later; Everbridge signed its original agreement on February 4 and closed on July 2, close to five months. Lenders that commit at signing carry the deal through the proxy, the vote and every regulatory review, which is why the gap between signing and closing is priced into commitment fees and flex terms, and why a sponsor's coverage banker presses for a timetable the financing can survive.

Both deals used a one-step merger approved at a special meeting. The alternative, a tender offer followed by a back-end merger without a vote under DGCL Section 251(h), is faster when regulatory review is short, as tender offers explained sets out. Either way the closing conditions run in parallel: the shareholder approval, the Hart-Scott-Rodino Act (HSR) waiting period (Everbridge filed on February 16, 2024, and the period expired on March 18), foreign direct investment filings, and review by the Committee on Foreign Investment in the United States (CFIUS) when foreign capital is in the buyer group, the risk that weighed on a rival bid in Barnes Group's auction.

Four Bank Seats on One Take-Private

A take-private can employ four sets of bankers with different clients, and the disclosure shows what each was paid:

The seat a coverage bank can take depends on what it already does for each party. Work for the sponsor or its portfolio companies may rule a bank out of the committee seat, or leave it there only after the committee reviews those fees, as happened with Barclays at R1, while the same relationship makes it a natural candidate for the buyer's adviser or financing role.

The committee's record, finally, is written while the deal is negotiated. Every proposal, counter and deadline in the R1 and Everbridge contests became a paragraph in a background section that shareholders read before voting and that a court can read later. For a sponsor, each bid letter in a take-private is a public document waiting for its date, and the bidders that won both deals wrote theirs to be read that way: executed commitments, finished contracts and a price the committee could defend.